The role of the mesenchymal stromal cell‐(MSC‐) derived secretome is becoming
increasingly intriguing from a clinical perspective due to its ability to stimulate endogenous …

Human mesenchymal stem cells (MSCs) are considered to be a promising source of cells in
regenerative medicine. They have large potential to differentiate into various tissue-specific …

Introduction Administration of mesenchymal stem cells (MSCs) represents a promising
treatment option for patients suffering from immunological and degenerative disorders …

Mesenchymal stem/stromal cells (MSC) show widespread application for a variety of clinical
conditions; therefore, their use necessitates continuous monitoring of their safety. The risk …

Mesenchymal stromal cells (MSCs) harbor great therapeutic potential for numerous
diseases. From early clinical trials, success and failure analysis, bench-to-bedside and back …

Cultured human umbilical cord mesenchymal stem cells (hUC-MSCs) are being tested in
several clinical trials and encouraging outcomes have been observed. To determine …

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) is an immune‐mediated
multifactorial disease, with high level of prevalence in humans and dogs. Our aim in this …

Large-scale expansion of highly functional adult human mesenchymal stem cells (aMSCs)
remains technologically challenging as aMSCs lose self renewal capacity and multipotency …

Capturing the promise of mesenchymal stem cell (MSC)-based treatments is currently
limited by inefficient production of cells needed for clinical therapies. During conventional ex …

To circumvent donor-to-donor heterogeneity which may lead to inconsistent results after
treatment of acute graft-versus-host disease with mesenchymal stromal cells generated from …